
Releases
TuHURA Biosciences Targets Key Milestones Following Capital Injection
Tampa-based TuHURA Biosciences reported its second-quarter financial results while outlining an aggressive development schedule for its immuno-oncology portfolio. Supported by a $50 million credit facility, the company aims to initiate new clinical trials and secure orphan drug designations for its lead cancer therapies before the end of the year.
























